Bharat Biotech submits paediatric Covid vaccine data to drugs regulator

Awaits DCGI approval; first vaccine to be tested on 2-6 year age group, likely to be available next month

Published: 07th October 2021 06:01 AM  |   Last Updated: 07th October 2021 01:09 PM   |  A+A-

Express News Service

BENGALURU: Bharat Biotech, the developer of the indigenously developed Covid-19 vaccine Covaxin, is said to have submitted its Phase II/III clinical trials data to drug regulator, Drugs Control General of India (DCGI).

With this, the wait for a paediatric Covid-19 vaccine for children aged over 2 years may soon be over, if DCGI approves Covaxin for use. 

According to the company’s spokesperson, the paediatric trial data of the 2-18 age group was analysed and has been submitted to the Central Drugs Standard Control Organisation (CDSCO).

It may be noted that Bharat Biotech Chairman and Managing Director Dr Krishna Ella recently met Union Health Minister Mansukh Mandaviya and told him that trial data will be submitted soon.

Karnataka Health Minister Dr K Sudhakar, who was present at the meet, had told the media about the same. 

The paediatric Covaxin is the same product and presentation as the vaccine being administered to adults. The company claims that Covaxin is the first Covid-19 vaccine to be tested on the 2-6 year age group.

“This is feasible due to the safety of the manufacturing platform and empirical evidence from Phase I, II, III clinical trials in adults,” the company statement said. 

As part of the Phase II/III trial, the two-dose Covaxin was administered to 525 children, 28 days apart.

Bharat Biotech had received the drug regulators’ nod to conduct trial on children in May this year. Sudhakar had said that vaccines for kids could be available next month.

In Karnataka, 90 children from Mysuru’s Cheluvamba Hospital, attached to Mysore Medical College and Research Institute (MMCRI), were part of the trial.

It is one among the five medical institutions that were part of the trial. Dr Pradeep N, Principal Investigator and Associate Professor, Department of Paediatrics, MMCRI, had earlier told TNIE that the children had completed three trials and were healthy and fine. 

Covaxin was developed by Bharat Biotech along with the Indian Council of Medical Research (ICMR) and National Institute of Virology (NIV), Pune. 

It may be noted that Zydus Cadila’s DNA vaccine has been approved for children aged 12 years and above.

It is yet to be available in the market. Meanwhile, Serum Institute of India is also conducting trials on children for the Novavax vaccine (Covovax) and recently started trials on 7-11 year old children.


Disclaimer : We respect your thoughts and views! But we need to be judicious while moderating your comments. All the comments will be moderated by the editorial. Abstain from posting comments that are obscene, defamatory or inflammatory, and do not indulge in personal attacks. Try to avoid outside hyperlinks inside the comment. Help us delete comments that do not follow these guidelines.

The views expressed in comments published on are those of the comment writers alone. They do not represent the views or opinions of or its staff, nor do they represent the views or opinions of The New Indian Express Group, or any entity of, or affiliated with, The New Indian Express Group. reserves the right to take any or all comments down at any time.

flipboard facebook twitter whatsapp